What Is Foundayo (Orforglipron)? The GLP-1 Weight Loss Pill, Explained

In April 2026, the FDA approved Foundayo® (orforglipron) — Eli Lilly's once-daily pill for chronic weight management, and the first GLP-1 weight-loss medication you can take any time of day with no food or water restrictions. It's a genuinely new option in a category that has been injection-first, and search interest has exploded since approval.

One thing up front, in the interest of honesty: Pallas does not offer Foundayo®. This explainer exists because our patients and readers are asking about it, and there's a lot of confusion — and some outright misinformation — circulating. Here's what it is, what the evidence shows, and what to watch out for.

What Foundayo is and how it works

Foundayo® works the same way the injectable GLP-1 medications do: it activates the GLP-1 receptor, which reduces appetite, slows stomach emptying, and helps regulate blood sugar. The difference is chemistry. The injectable GLP-1s — semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) — are large, fragile molecules that digestion would destroy, which is why they're injected. Orforglipron is a small-molecule drug: chemically sturdy enough to survive the digestive tract, absorb reliably as a tablet, and skip the cold chain entirely.

That's what makes it different from the one oral GLP-1 that came before it. Rybelsus® (oral semaglutide, approved for type 2 diabetes — not weight management) must be taken on an empty stomach with a small sip of water, then a 30-minute wait before eating. Foundayo® has none of those restrictions — any time of day, with or without food.

What the trials showed

In Lilly's ATTAIN trial program, adults with obesity (without diabetes) taking Foundayo® lost an average of about 11% of their body weight at the highest dose; adults with obesity and type 2 diabetes lost about 10%. The most common side effects were gastrointestinal — nausea, constipation, vomiting — the familiar GLP-1 profile, and doses are stepped up gradually to manage them.

For context: in their own separate trials, the FDA-approved injectables produced larger average losses — about 15% for Wegovy® in STEP-1 and about 20% for Zepbound® in SURMOUNT-1. Those were different trials with different populations, not head-to-head comparisons against Foundayo®, so treat the numbers as rough guideposts rather than a ranking. The honest summary of the current evidence: the pill trades some average weight loss for the convenience of never injecting.

Who might care about a pill instead of an injection

• People with genuine needle aversion — the group most likely to delay or abandon treatment entirely.
• Frequent travelers, since there's no refrigeration, no sharps, and nothing to declare at security.
• People who value privacy — a tablet in a pill organizer is invisible in a way a weekly injection kit isn't.

Whether any GLP-1 medication — pill or injection — is appropriate for you is a clinical decision made with a licensed provider after reviewing your full history.

Can you get compounded orforglipron? (No — and be careful.)

As search interest in Foundayo® grows, expect to see sellers offering "compounded orforglipron." Walk away. Orforglipron is a newly approved, patent-protected small molecule; it is not among the substances that US compounding pharmacies are permitted to use, and there is no legitimate compounded version. Anything sold as compounded or "research" orforglipron is a counterfeit red flag.

This is different from compounded semaglutide and tirzepatide, which licensed US compounding pharmacies may prepare per-patient when a prescriber documents a specific clinical need. Even then, compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality — and the trial results above apply only to the FDA-approved products studied, not to compounded preparations.

Where Pallas fits

Pallas doesn't offer Foundayo® today. What we do offer, when a licensed clinician determines it's appropriate: FDA-approved Wegovy®, Ozempic®, Zepbound®, and Mounjaro® (cash-pay only; insurance is not billed), and compounded semaglutide and tirzepatide — including a compounded oral semaglutide tablet for people who prefer not to inject. As with any new medication, we evaluate additions to our formulary on clinical merit, sourcing, and regulatory fit — not on hype cycles.

References

1. Eli Lilly and Company. FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 2026.
2. U.S. Food and Drug Administration. NDA 220934 approval letter — orforglipron. April 2026.
3. Drugs.com. Foundayo (orforglipron) FDA approval history.

Bottom line: Foundayo® (orforglipron) is real, FDA-approved, and a meaningful shift — the first take-anytime GLP-1 pill for weight management, with roughly 11% average weight loss in its trials. It isn't available compounded, it isn't the same molecule as Wegovy® or Ozempic®, and Pallas doesn't dispense it today. If you're weighing your options, the right starting point is a licensed clinician who can look at your history and lay out what actually fits.